ArticleAmerican journal of Alzheimer's disease and other dementias
Restoration of Memory Along With Neurogenic Enhancement by Therapeutic Botulinum Neurotoxin in a Preclinical Model of Parkinson's Disease.
Article in American journal of Alzheimer's disease and other dementias. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neuroprotective Potential of Synaptamide in MPTP-Induced Parkinson's Disease.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra (SN), leading to motor impairments, while hippocampal dysfunction contributes to memory deficits. Botulinum neurotoxin (BoNT), a therapeutic modulator of acetylcholine (ACh) release, its cognitive effects remain underexplored. We investigated the effect of BoNT on spatial learning, memory, microglia and hippocampal neurogenesis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD. Behavioral tests, including the open field, novel object recognition, and Morris water maze, demonstrated significant improvements in locomotion, learning, and memory with BoNT treatment. BoNT increased the number of doublecortin (DCX)-positive immature neurons and percentage of bromodeoxyuridine (BrdU)/neuronal nuclei (NeuN) double-positive cells, while the reduced number of microglia was evident in the hippocampal dentate gyrus (DG). Additionally, histological analyses revealed BoNT-mediated protection of pyramidal neurons in hippocampal cornu ammonis (CA)-1 and CA3 regions. These findings suggest that BoNT mitigates memory deficits by promoting neurogenesis in experimental PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.